Asian Pacific Journal of Cancer Prevention

  • 제16권13호
  • /
  • Pages.5477-5482
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Analysis of Prethrombotic States in Patients with Malignant Tumors

  • Cui, Lin (Department of Oncology, Taizhou Second People’s Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Sun, You-Hong (Department of Oncology, Taizhou Second People’s Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Chen, Jue (Meidicall college of Yangzhou University) ;
  • Wang, Lu (Department of Oncology, Taizhou Second People’s Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Liu, Jian-Jun (Department of Oncology, Taizhou Second People’s Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Zhou, Xiang-Rong (Department of Oncology, Taizhou Second People’s Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Ding, Jie (Department of Oncology, Taizhou Second People’s Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Liu, Xing-Xiang (Department of Oncology, Taizhou Second People’s Hospital, the Affiliated Hospital of Yangzhou University) ;
  • Huang, Xin-En (Department of Chemotherapy, Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
  • 발행 : 2015.08.03
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: This study aimed to investigate the incidence and risk factors for a prethrombotic state in patients with malignant tumors. Materials and Methods: Plasma d-dimer (D-D) in patients with malignant tumors was measured. Abnormal rates of D-D and possible risk factors like gender, age, type of tumor, and staging of tumor were analyzed. Results: Of 1,453 patients, 629 demonstrated plasma D-D abnormality (43.3%). The D-D abnormal rate of male patients (n=851, 43.5%) was not statistically significantly different from that for female patients (n=602, 43.0%) (p>0.05). D-D abnormal rate increased with age and was statistically significant among different age groups (p<0.05). Regarding staging of tumor, D-D abnormal rate in patients with phase I was 2.0%, 6.2% in phase II, 47.6% in phase III and 83.1% in phase IV, with statistically significant differences between phase III and II, as well as phase III and IV (p<0.01). Conclusions: A prethrombotic state was closely related to malignancy of tumors. The risk factors for a prethrombotic state include age and tumor stage.

키워드

참고문헌

  1. Asanuma K, Wakabayashi H, Okamoto T, et al (2012). The Thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone. Breast Cancer, 20, 241-6.
  2. Bergmann JF, Kher A (2005). Venous thromboembolism in the medically ill patient: a call to action. Int J Clin Pract, 59, 555-61. https://doi.org/10.1111/j.1368-5031.2005.00529.x
  3. Biggerstaff JP, Seth N, Amirkhosravi A, et al (1999). Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin Exp Metastasis, 17, 723-30. https://doi.org/10.1023/A:1006763827882
  4. Bobek V (2012). Anticoagulant and fibrinolytic drugs-possible agents in treatment of lung cancer? Anticancer Agents Med Chem, 12, 580-8. https://doi.org/10.2174/187152012800617687
  5. Chen F, Abulizi A, Huang J (2012). Detections of PT, APTT, FBG and PLT and their clinical significance in patients with esophageal carcinoma, gastric carcinoma and rectal carcinoma. J Mod Oncol, 20, 768-71.
  6. Chen Ming (2014). The diagnostic value of FDP and D-dimer test indicators for colorectal cancer with liver metastases. Chin J Clin Oncol Rehabil, 21, 273-5.
  7. Cui L, Jiang Y, Liu X, et al (2012). Clinical analysis of the relation of malignant tumor and thromboembolic disease in 20 cases. Cancer Res Clinic, 24, 843-4.
  8. Douma RA, le Gal G, Sohne M, et al (2010). Potential of an age adjusted Ddimer cut-off value to improve the exclusion of pulmonary embolism in older patients: are trospective analysis of three large cohorts. BMJ, 340, 1475. https://doi.org/10.1136/bmj.c1475
  9. Edoute Y, Haim N, Rinkevich D, et al (1997). Cardiac valvular vegetations in cancer patients a prospective echocardiographic study of 200 patients. AM J Med, 102, 252-8. https://doi.org/10.1016/S0002-9343(96)00457-3
  10. Farge D, Durant C, Villiers S, et al (2010). Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. Thromb Res, 125, 108-16. https://doi.org/10.1016/S0049-3848(10)70027-X
  11. He S, Fen L, Wang F, et al (2010). Precaution and treat of prethrombotic state of malignant tumors. World Chin Med, 5, 53.
  12. Hu L, Yang H, Su L, et al (2010). Clinical research of the hypercoagulable state in 180 patients with malignant tumor. Med Res Edu, 27, 30-2.
  13. Huang Y, Chen J, Yu N, et al (2012). Clinical Significance of plasma D-dimer ideetection in patients with breast cancer. Clin Misd Misther, 25, 79-81.
  14. Imberti D, Di Nisio M, Donati MB, et al (2009). Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res, 124, 32-40. https://doi.org/10.1016/j.thromres.2009.08.006
  15. Isaia G, Greppi F, Ausiello L, et al (2011). D-dimer plasma concentrations in an older hospitalized population. J Am Geriatr Soc, 59, 2385-6. https://doi.org/10.1111/j.1532-5415.2011.03690.x
  16. Jaffrelot M, Le Ven F, Le Roux PY, et al (2012). External validation of a D-dimer age-adjusted cut-off for the exclusion of pulmonary embolism. Thromb Haemost, 107, 1005-7. https://doi.org/10.1160/TH11-10-0706
  17. Jiang Z, Sang H, Ge H, et al (2009). The study of prethrombotic state in patients with lung cancer. Zhongguo Fei Ai Za Zhi, 12, 44-8.
  18. Kakkar AK, Levine MN, Kadziola Z, et al (2004). Low molecular weight heparin therapy with dalteparin and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol, 22, 1944-8. https://doi.org/10.1200/JCO.2004.10.002
  19. Koh SC, Razvi K, Chan YH, et al (2011). The association with age human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer. Arch Gynecol Obstet, 284, 183-90. https://doi.org/10.1007/s00404-010-1605-z
  20. Linkins LA, Bates SM, Lang E, et al (2013). Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med, 158, 93-100. https://doi.org/10.7326/0003-4819-158-2-201301150-00003
  21. Liu X, Xu X (2013). Research progress on malignant tumor and blood hypercoagulability. Guangdong Medical, 34, 1295-7.
  22. Lopez JA, J Chen J (2009). Pathophysiology of venous thrombosis.Thromb Res, 123, 30-4.
  23. Ma Y, Qian Y, Lv W (2007). The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma. J Int Med Res, 35, 678-84. https://doi.org/10.1177/147323000703500512
  24. Ouyang X, Chen Z, Tu X, et al (1999). Study on relationship between plasma d-dimer concentration and Cl inical staging of primary hepatic cancer. Chin J Clinic Oncol, 26, 128-9.
  25. Rybicki FJ, Prevedello LM, Di Salvo DN, et al (2010). Imaging presentation of venous thrombosis in patients with cancer. AJR Am J Roentgenol, 194, 1099-108. https://doi.org/10.2214/AJR.09.2501
  26. Spyropoulos AC, Hussein M, Lin J, et al (2009). Rates of venous thromboembolism occurrence in medical patients among the insured population. Thromb Haemost, 102, 951-7.
  27. Sud R, Khorana AA (2009). Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res, 123, 18-21. https://doi.org/10.1016/S0049-3848(09)70137-9
  28. Tan N, Zhou D, Qin L, et al (2014). Changes and clinical significance of plasma fibrinogen, d-dimer and antithrombin III levels in patients with lung cancer. Guangxi Med J 36, 326-8.
  29. Wang M, Jiang M, Jiang R, et al (2012). Application value of monitoring D-dimer for perioperative ovarian cancer patients. China Oncol, 22, 381-4.
  30. Wei J (2012). Clinical observation of elderly patients with chronic pulmonary heart disease with high coagulation state. China Community Doctors, 14, 111-2.
  31. Yan S, Wang D, Li X, et al (2014). Clinical research on high coagulation state and thrombosis in patients with cancer. Chin J Clin Oncol Rehabil, 21, 542-4.
  32. Zeng L, Liu Y, Liu X, et al (2012). The malignant tumor's monitoring for the hight cogulation state in the eldly patients. Chin J Gerontol, 32, 609-10.
  33. Zhang X, Fang J, Chen Y, et al (2014). A retrospective analysis of continuous detection of serum d-dimer in malignancy dying patients. Cancer Res Prev Treat, 41, 350-2.
  34. Zhang Y, Yang N, Wang F, et al (2012). The value of observe the blood coagulating function and d-dimer in late malignant tumor patients. Pract J Cancer, 27, 165-7.
  35. Zhao J, Jiang D (2013). The hypercoagulable state and intervention of malignant tumor. Oncol Prog, 11, 48-52.

피인용 문헌

  1. Analysis of Relationships Between Prethrombotic States and Cervical Cancer vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.6163
  2. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
  3. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485
  4. Effect of Peripheral Blood CD4 + CD25 + Regulatory T Cell on Postoperative Immunotherapy for Patients with Renal Carcinoma vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2027
  5. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress vol.140, pp.4, 2017, https://doi.org/10.1002/ijc.30498
  6. Recurrent stroke in a patient of lung cancer without pulmonary mass vol.97, pp.5, 2018, https://doi.org/10.1097/MD.0000000000009815